OptimizeRx Corporation. (NASDAQ:OPRX) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET
Company Participants
William Febbo - Chief Executive Officer
Edward Stelmakh - Chief Financial and Operating Officer
Stephen Silvestro - Chief Commercial Officer
Marion Odence-Ford - General Counsel and Chief Compliance Officer
Andrew D’Silva - Senior Vice President, Corporate Finance
Conference Call Participants
Ryan Daniels - William Blair
Sean Dodge - RBC Capital Markets
Eric Martinuzzi - Lake Street
Operator
Good afternoon, everyone. And thank you for joining OptimizeRx’s Second Quarter Fiscal 2023 Earnings Discussion. With us today is the Chief Executive Officer of OptimizeRx, William Febbo. He is joined by company Chief Financial Officer, Ed Stelmakh; Chief Commercial Officer, Steve Silvestro; General Counsel and Chief Compliance Officer; Marion Odence-Ford; and Senior Vice President of Corporate Finance, Andrew D’Silva.
At the conclusion of today’s earnings call, I will provide some important cautions regarding the forward-looking statements made by management during today’s call. I would like to remind everyone that today’s call is being recorded and will be made available for replay via webcast only. Instructions are included in today’s press release and in the Investors section of the company’s website.
Now I would like to turn the call over to OptimizeRx CEO, William Febbo. Sir, please go ahead.
William Febbo
Good afternoon everyone and thank you for joining our second quarter earnings call today. While we are disappointed with the quarter’s results, we are seeing unprecedented change in the pharma industry in their adoption of digital and tech-enabled marketing solutions. We are now coming out of the post COVID heavy piloting phase within pharma and the basic decision making has slowed as they look for scalable partners. We saw this firsthand with many clients. We are evaluating their marketing models, product delays and a higher demand for data driven solutions.
Despite this, we remain excited about our business. We are laser-focused on optimizing our resources on the future of digital marketing in health care. In Q2, we saw revenue push into the second half due to clients needing more time for medical, legal and regulatory review. While delays are frustrating and impact at our stage, they are typical in today's environment and we do not view them as a negative indicator. We have solid confidence in our core offerings, which built us up to where we are today, and we believe it will drive growth into the future as we get past the headwinds mentioned on previous calls.